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Abstract
Background: In a randomized controlled trial of 628 Chinese patients with type 2 diabetes receiving multidisciplinary
care in the Joint Asia Diabetes Evaluation (JADE) Progam, 372 were randomized to receive additional telephone-based
peer support (Peer Empowerment And Remote communication Linked by information technology, PEARL) intervention.
After 12 months, all-cause hospitalization was reduced by half in the PEARL group especially in those with high
Depression Anxiety and Stress Scale (DASS) scores.
Methods: We used stratified analyses, negative binomial regression, and structural equation modelling (SEM) to examine
the inter-relationships between emotions, self-management, cardiometabolic risk factors, and hospitalization.
Results: Hospitalized patients were older, more likely to have heart or kidney disease, and negative emotions than
those without hospitalization. Patients with high DASS score who did not receive peer support had the highest
hospitalization rates. After adjustment for confounders, peer support reduced the frequency of hospitalizations by
48% with a relative risk of 0.52 (95% CI 0·35–0·79;p = 0·0018). Using SEM, improvement of negative emotions
reduced treatment nonadherence (Est = 0.240, p = 0.034) and hospitalizations (Est=−0.218, p = 0.001). The latter
was also reduced by an interactive term of peer support and chronic kidney disease (Est = 0.833, p = < 0.001) and
that of peer support and heart disease (Est = 0.455, p = 0.001).
Conclusions: In type 2 diabetes, improvement of negative emotions and peer support reduced hospitalizations,
especially in those with comorbidities, in part mediated through improving treatment nonadherence. Integrating
peer support is feasible and adds value to multidisciplinary care, augmented by information technology,
especially in patients with comorbidities.
Trial registration: NCT00950716 Registered July 31, 2009.
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Background
In clinical trial settings, diabetes complications are
preventable with modifiable risk factor control. Des-
pite recent advances in therapeutics, many patients
have suboptimal control of cardiometabolic risk fac-
tors. In the United States, less than half of the pa-
tients have attained recommended goals for diabetes
care [1]. In some surveys, patients with type 2 dia-
betes had 30% increased risk of hospitalization [2]
and 50% increased inpatient mortality rate compared
to those without diabetes [3]. The co-occurrence of
comorbidities, particularly poor mental health, also
increases the risk of health care utilization in people
with diabetes [4, 5].
One of the greatest challenges in diabetes management
is to motivate, initiate, and sustain behavioural changes
to maintain metabolic control [6]. While frequent con-
tacts with health care providers (HCP) improves risk fac-
tor control [7], peer support has the potential to
promote self-management and care quality, especially in
low resource settings [8, 9]. “Peer support” is defined as
“support from a person who has experiential knowledge
of a specific behaviour or stressor and similar character-
istics as the target population” [8]. Herein, peer support
can empower patients through building trust from
shared experiences and by providing informational and
emotional support [9].
In type 2 diabetes, peer support has been shown to
improve clinical, behavioural, and psychological out-
comes [10, 11]. Peer support has also been shown to
reduce health care utilisation and cost, although re-
sults have not always been consistent [12, 13]. In
2007, we launched a nurse-coordinated diabetes care
program augmented by the web-based Joint Asia Dia-
betes Evaluation Program (JADE Program) [14]. We
randomized 628 Chinese patients with type 2 diabetes
receiving JADE care to peer support versus JADE
alone to evaluate whether a telephone-based peer
support program (Peer Empowerment And Remote
communication Linked by information technology,
PEARL program) would further improve risk factor
control and all-cause hospitalizations [15]. At the end
of 12 months, patients in both arms had similar im-
provements in glycemic control and cardiometabolic
risk factors. However, the addition of PEARL peer
support intervention reduced hospitalization rate
compared to JADE care alone, especially in patients
with the highest levels of negative emotion as mea-
sured by the Depression, Anxiety, and Stress Scale
(DASS-21) with a relative risk (RR) of 0.15 (0.07–
0.34, p < 0.0001). In this post-hoc analysis, we
performed detailed analysis to investigate the inter-
relationships between emotions, medication adher-
ence, peer support, and hospitalizations.
Methods
Study design and hypothesis
The PEARL study was a 12-month randomized con-
trolled trial evaluating the effect of peer support on
metabolic control and hospitalizations from 2009 to
2010. The primary results of the PEARL study were pub-
lished with detailed explanation of methods [15]. Our
overarching hypothesis is that a telephone-based peer
support intervention may improve negative emotions
and medication adherence, thereby improving risk factor
control and reducing all-cause hospitalization rates. To
further explore the trial findings, we performed the fol-
lowing post-hoc analyses:
1) Univariate analyses of clinical profiles stratified by
hospitalization status (ever hospitalized versus never
hospitalized)
2) Univariate analyses of clinical profiles stratified by
the median levels of negative emotions as measured
by the Depression Anxiety Stress Scale (DASS-21)
[15].
3) Kaplan Meier and negative binomial regression
analyses to evaluate the impact of peer support and
negative emotions (DASS-21) on hospitalizations.
4) Structural equation modelling (SEM), which
provides a multivariate lens while addressing
confounding by multicollinearity, to identify
independent key factors leading to hospitalization.
Ethics, consent, and permissions
This study was approved by the Joint Chinese University
of Hong Kong – New Territories East Cluster (CUHK-
NTEC) Clinical Research Ethics Committee. All willing
patients gave written informed consent and completed
validated questionnaires for evaluation of psychological-
behavioural measures at baseline and at the end of the
study, and were randomized to the PEARL peer support
intervention within the JADE program or the JADE pro-
gram alone in a 1:1 ratio.
Setting
Hong Kong has a subsidised public healthcare system with
the Hospital Authority (HA) providing the bulk of chronic
care through its hospitals and clinics which share a unified
electronic medical record known as the Clinical Manage-
ment System (CMS). Based on a series of epidemiological
and interventional studies, the JADE Program was estab-
lished in 2007 to deliver technologically-enhanced and inte-
grated multidisciplinary care through the use of structured
data collection, risk stratification, and evidence-based deci-
sion support [14].
This 12-month randomized study was conducted in three
HA diabetes centres where the JADE Program was imple-
mented. Consecutive patients were recruited throughout
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the year and randomized as they consented. The JADE Pro-
gram included an initial 4-h nurse-led assessment including
history taking, blood/urine collection, and eye/ft examin-
ation where the data were entered into the online portal
which electronically generated personalised reports
regarding the patient’s risk factors, complications, and risk
categories based on findings from the Hong Kong Diabetes
Register [14]. Frequency of follow-up visits was
recommended based on individualized risk assessment.
Chronic kidney disease (CKD) was defined as estimated
glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 or
dialysis-dependence. Heart disease was defined as a history
of myocardial infarction, coronary revascularization, or
heart failure.
The PEARL intervention
Peer supporters
The details of the training program for peer sup-
porters had been reported [15]. In brief, 33 motivated
patients with HbA1c less than 8% (64 mmol/mol)
who had completed a ‘Train the Trainer’ program
conducted during four 8-h workshops agreed to be
peer supporters. The program focused on mindset,
empathic listening, questioning skills, and counselling
skills regarding lifestyle modification. Eligibility in-
cluded Chinese adult patients with type 2 diabetes
(18–70 years) who underwent the JADE comprehen-
sive assessment. Exclusions included those in the low-
est JADE Risk Category (no diabetes complications,
≤1 risk factor, and low-risk score) [15] or those with
suicidal ideation. Each peer supporter was introduced
to 10 peers during a 2-h session by nurses and was
expected to contact each peer at least 12 times over
12 months in a phone or face-to-face meeting. Con-
versations or meetings were guided by a script, which
addressed diet, exercise, self-monitoring of blood glu-
cose, sick day management, foot care, emotional sup-
port, resources for information, and clinical care. Peer
supporters were asked to record the duration of each
call and any relevant details for the call. The doctors,
nurses, and project coordinators met all peer sup-
porters on three occasions for a half-day meeting to
share experiences. Confidentiality of patient informa-
tion was emphasised at each meeting.
Peers
All Chinese patients with type 2 diabetes aged 18 to
70 years who underwent JADE comprehensive assess-
ments who were receptive were eligible. Exclusion cri-
teria included illiteracy, inability to communicate in
Chinese, those in JADE Risk Category 1 (no complica-
tions, ≤1 risk factor, and low-risk score), and those re-
ceiving psychiatric treatment.
Main outcomes and measures
The CMS captured all hospitalizations within the Hong
Kong public health care system, classified by the Inter-
national Classification of Diseases, Ninth Revision (ICD-
9) codes on discharge. Measures included the total
number of all-cause hospitalizations for each group, fre-
quency of hospitalization per patient, and the total
length of stay (TLOS) per patient admission, defined as
a count of day admissions plus nights spent in a hospital.
Measurements were censored using the CMS on the day
of repeat assessment or after 12 months in those who
did not return. All patients completed validated ques-
tionnaires for psychometric measures including the 9-
item Patient Health Questionnaire (PHQ-9) for depres-
sive symptoms [16], the 21-item Depression Anxiety
Stress Scale (DASS-21) with sub scores for depression,
anxiety and stress [17], the 15-item Chinese Diabetes
Distress Scale (CDDS-15) for diabetes-related distress
[18], and the 4-item Morisky Medication Adherence
Scale for medication adherence [19].
Statistical analysis
For each patient, we censored the hospitalization data at
their 1 year reassessment. For patients who did not re-
turn at 1 year for assessment, we retrieved their results
from the Health Authority CMS, if available. Descriptive
analyses were presented as mean ± SD or frequency (%)
stratified by hospitalization status and negative emo-
tions. The Pearson χ2 test, Fisher exact test, t test,
Wilcoxon paired test, and Mann-Whitney test were used
for comparisons, as appropriate. Significant negative
emotion was defined as the top quintile value of DASS-
21 score ≥ 17. We used unadjusted Kaplan Meier “time
to event” estimates to illustrate the relationship between
peer support and negative emotion on time to first
hospitalization. Since the majority of patients were not
hospitalized, we used zero-inflated negative binomial re-
gression to estimate the relative risk (RR) for the fre-
quency and TLOS of hospitalizations with 95%
confidence interval (CI) adjusted for age, sex, disease
duration, and risk category to compare with the un-
adjusted findings. A p < 0.05 (2-tailed) was considered
significant. We applied intention-to-treat analysis to all
randomized patients using the Statistical Package for So-
cial Sciences (version 20.0, Chicago, USA) for descriptive
analysis and Statistical Analysis Software for the negative
binomial regression analysis (version 9.3). Missing data
were omitted from the analyses.
Structural equation modelling (SEM)
We have chosen to use SEM because it allows examin-
ation of relationships among observed and latent (unob-
served) variables. Moreover, SEM eliminates possible
multicollinearity induced by highly correlated indicators
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and provides simple interpretations among observed and
latent variables [20]. We first used factor analysis to
group highly correlated measured variables into corre-
sponding latent factors taking measurement errors into
account. The structure of our factor loading was deter-
mined on subjective, a priori clinical knowledge. These
included 1) “hospitalization” (grouped by TLOS and fre-
quency of hospital admissions); 2) “change in negative
emotions” from baseline to end of study (grouped by
changes in CDDS-15, PHQ-9, and DASS-21); 3) “blood
pressure” from systolic and diastolic blood pressure; 4)
“lipids” from triglycerides, LDL-C, and total cholesterol;
and 5) “obesity” from body mass index (BMI) and waist
circumference. We did not include HbA1c due to similar
changes between the two groups (PEARL: − 0.30 (− 0.47
to − 0.12) and non-PEARL group: − 0.29 (− 0.47 to −
0.12) at one year [15]. In the SEM model, we included
age, gender and peer support (yes/no: 1/0) as determi-
nants for hospitalization based on results from our pri-
mary paper [15]. Supported by other studies, we
included medication adherence (measured by the 4-item
Morisky Medication Adherence Scale) [21] and diabetes
complications [CKD and heart disease coded as 1/0)]
known to increase health care utilization [22]. We
regressed multiple equations linking peer support to
“hospitalization” through “change in negative emotions”,
“adherence”, “blood pressure”, “lipids”, and “obesity” fac-
tors (Fig. 1). We considered the effects of “change in
negative emotions” on medication adherence and tested
the interactive terms of (peer support×CKD) and (peer
support×heart disease) on “hospitalization”. Mplus soft-
ware was used to obtain the estimates and goodness-of-
fit indices with optimal indexes defined as Chi square
test> 0.05, root mean square error of approximation
smaller than 0.08 and Comparative Fit Index (CFI) value
approximate to 1 [23].
Results
The study participants’ clinical profiles have been published
and were similar between the 2 groups [age:54.7 ± 9.3 years;
57% men; disease duration:9.4 ± 7.7 years; HbA1c: 8.2% ±
1.6% (66 ± (− 6)mmol/mol); systolic BP:136 ± 19 mmHg;
LDL-C:2.89 ± 0.82 mmol/L; 17.4% cardiovascular-renal dis-
ease; 34.9% insulin-treated] [15]. After a follow-up period
of 414 ± 55 days, 144 (22.9%) patients were hospitalized at
least once. They were older, more likely to receive multiple
medications, and 2–3 times more likely to have CKD and
heart disease and had higher DASS-21 scores than those
without hospitalization (Table 1). Those with the most
negative emotions (DASS-21 ≥ 17, n = 124) were more
likely to be female, less well-educated, more obese, had
more depressive symptoms and poorer medication adher-
ence than those with lower scores.
On Kaplan Meier analysis, patients who had DASS-21 ≥
17 and did not receive peer support had the highest
hospitalization rates than the other 3 groups stratified by
Fig. 1 Proposed structural equation model with hypothesized explanatory and outcome variables (rectangle: measured variables; oval: latent
variables) and interlinking paths to explain the multi-causality of hospitalization (15). Abbreviations: PEARL: peer support intervention, Frequency:
number of hospitalization episodes, Stay: Length of hospital stay, PHQ-9: 9-item Patient Health Questionnaire assessing depressive symptoms,
DASS-21: 21-item Depression Anxiety Stress Scale, CDDS-15: 15-item Chinese Diabetes Distress Scale, Medication Adherence: 4-item Morisky Medi-
cation Adherence Scale, CKD: Chronic Kidney Disease with eGFR 15–60 ml/min/1.73 m2, CVD: Cardiovascular disease including coronary heart dis-
ease (myocardial infarction, unstable angina, percutaneous coronary intervention, coronary bypass operation), stroke, peripheral vascular disease
(lower extremity amputation, absent foot pulses with ankle:brachial ratio < 0.9 and/or lower limb revascularization), BP: Blood pressure, SBP (sys-
tolic) DBP (diastolic), TC/LDL-C: Total cholesterol/LDL-cholesterol, TG: Triglycerides, BMI: Body mass index, Waist: waist circumference, N.B. Baseline
explanatory measures were analyzed
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Table 1 Clinical, biochemical, psychological and behavioural parameters stratified by hospitalization and baseline DASS-21 score
Hospital admission Baseline DASS-21 score
No (n = 484) Yes (n = 144) P value < 17 (n = 503) ≥17 (n = 124) P value
Age, years 54·1 ± 9·4 56·7 ± 8·6 0·003 54·9 ± 9·1 54·0 ± 9·7 0·358
Male, n(%) 274 (56·6) 81 (56·3) 0·939 295 (58·6) 59 (47·6) 0·026
Diabetes duration, years 9·1 ± 7·7 10·3 ± 7·8 0·122 9·4 ± 7·7 9·5 ± 8·0 0·845
Education
< 6 years 165 (34·1) 63 (43·8) 0·079 171 (34·0) 57 (46·0) 0·005
6–11 years 247 (51·0) 62 (43·1) 252 (50·1) 56 (45·2)
> 11 years 72 (14·9) 19 (13·2) 80 (15·9) 11 (8·9)
Complications
Chronic kidney disease 25 (5·2) 21 (14·8) < 0·001 34 (6·8) 12 (9·8) 0·251
Diabetic retinopathy 166 (34·3) 56 (38·9) 0·312 169 (33·6) 53 (42·7) 0·057
All heart events 41 (8·5) 26 (18·3) 0·001 52 (10·4) 15 (12·1) 0·586
JADE Risk categories
Very high risk 73 (15·1) 36 (25·0) 0·003 86 (17·1) 23 (18·5) 0·474
High risk 385 (79·5) 104 (72·2) 391 (77·7) 97 (78·2)
Medium risk 24 (5·0) 4 (2·8) 24 (4·8) 4 (3·2)
Low risk 2 (0·4) 0 (0·0) 2 (0·4) 0 (0·0)
Treatments
Insulin 165 (34·1) 54 (37·5) 0·451 174 (34·6) 45 (36·3) 0·722
Oral anti-diabetic drugs 407 (84·1) 127 (88·2) 0·226 423 (84·1) 110 (88·7) 0·197
On BP drugs 305 (63·0) 104 (72·2) 0·042 327 (65·0) 81 (65·3) 0·948
On lipid lowering drugs 194 (40·1) 84 (58·3) < 0·001 218 (43·3) 59 (47·6) 0·394
Risk factors control
Body mass index, kg/m2 26·8 ± 4·3 27·1 ± 5·0 0·563 26·6 ± 4·3 27·8 ± 4·8 0·009
Systolic blood pressure, mmHg 135·6 ± 18·2 136·4 ± 20·9 0·633 136·2 ± 18·4 134·2 ± 20·7 0·307
Diastolic blood pressure, mmHg 80·2 ± 10·5 79·0 ± 11·2 0·227 80·3 ± 10·5 78·6 ± 11·5 0·115
Hemoglobin A1c, % (mmol/mol) 8.2 ± 1.6 (66.0 ± 17.9) 8.2 ± 1.6 (65.7 ± 17.7) 0.867 8.2 ± 1.6 (65.6 ± 17.7) 8.3 ± 1.7 (67.2 ± 18.7) 0.394
Total cholesterol, mmol/L 4·91 ± 1·07 4·71 ± 1·06 0·044 4·83 ± 1·07 4·99 ± 1·08 0·160
Triglyceride, mmol/L 1·40 (1·00–2·00) 1·49 (1·00–1·97) 0·704 1·40 (1·00–1·97) 1·52 (1·00–2·30) 0·076
HDL-C, mmol/L 1·20 ± 0·36 1·23 ± 0·36 0·433 1·21 ± 0·35 1·17 ± 0·37 0·265
LDL-C, mmol/L 2·92 ± 0·78 2·77 ± 0·91 0·046 2·86 ± 0·79 2·99 ± 0·91 0·131
Estimated GFR, ml/min/1·73m2 111·9 ± 33·1 102·6 ± 36·8 0·005 110·2 ± 33·7 107·7 ± 36·1 0·471
Microalbuminuria 127 (26·6) 39 (27·5) 0·843 134 (27·0) 31 (25·6) 0·765
Psychological assessment
PHQ-9 score 4·1 ± 4·1 4·7 ± 4·2 0·131 3·1 ± 3·1 8·6 ± 4·9 < 0·001
CDDS-15 score 36·8 ± 13·5 37·0 ± 12·2 0·849 34·8 ± 12·8 45·1 ± 11·6 < 0·001
DASS-21 score
Total 9·3 ± 10·0 14·0 ± 14·0 < 0·001 5·9 ± 4·7 28·7 ± 11·3 < 0·001
DASS-depression 2.75 ± 3.80 4.23 ± 5.02 0.001 1.53 ± 1.85 9.48 ± 4.78 < 0·001
DASS-anxiety 2.71 ± 3.12 4.20 ± 4.63 < 0·001 1.76 ± 1.65 8.33 ± 4.39 < 0·001
DASS-stress 3.79 ± 3.97 5.24 ± 5.02 0.002 2.55 ± 2.47 10.59 ± 4.01 < 0·001
Medication adherence
High 200 (43·8) 65 (47·8) 0·248 225 (47·3) 40 (34·5) 0·021
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peer support and DASS-21 scores (Fig. 2). Upon stratifica-
tion by presence and absence of negative emotions at base-
line, peer support tended to improve negative emotions
reaching significance for medication adherence in those
with the highest levels of negative emotions. Using negative
binomial regression, and adjusting for age, gender, disease
duration, JADE risk category, and DASS-21 score, peer sup-
port reduced hospitalization [RR 0.52 (95% CI 0.35–0.79)]
and shortened TLOS [RR 0.46 (95% CI 0.25–0.85)].
SEM findings
Based on our original conceptual framework, we formulated
a SEM that proposed explanatory pathways leading to
hospitalization (Fig. 1). The “blood pressure”, “lipids”, or
“obesity” pathways were not significant and thus were ex-
cluded from subsequent model building. After fitting data
to the different pathways, the final SEM (Fig. 3) demon-
strated a significant negative relationship of “change in
negative emotions” on “hospitalization” and direct positive
effect on “adherence”. In other words, patients with reduced
negative emotions were less likely to be hospitalized and
were more adherent to medications. Since hospitalized pa-
tients were more likely to have CKD, heart disease, and
negative emotions, we also tested the interactions between
peer support and comorbidities on hospitalization and
found strong positive interactions between peer support
and CKD, as well as peer support and heart disease on
hospitalization. Table 2 quantifies these relationships, which
indicate that in patients without CKD, the difference in
“hospitalization” values between the PEARL and non-
PEARL group was −0.026 compared to 0.807 (−0.026 +
0.833 = 0.807) in those with CKD (P = 0.001). For heart
disease, the respective values were −0.026 and 0.455
(−0.026 + 0.455 = 0.429) (P < 0.001). Our model’s goodness
of fit indices revealed a Chi-squared test p-value of 0.1330,
indicating that our SEM model supported our hypothesis
(i.e. not rejected by the data). The SEM model fitting was
optimal with the root mean square error of approximation
being 0.019, and the CFI value being 0.978, which were bet-
ter than the predetermined respective criteria for model fit-
ting (less than 0.08 and higher than 0.95).
Discussion
In our primary analysis of this 12-month randomized trial
of 628 Chinese patients type 2 diabetes receiving JADE-
augmented integrate care, cardio-metabolic risk factors im-
proved in both groups with peer support reducing
hospitalization rate, especially in those with negative emo-
tions [15]. While peer support has been shown to improve
glycemic control, few studies reported its impact on health-
care utilisation [24]. In this study, we used basic stratifica-
tion analyses to identify differentiating characteristics
between patients who had been hospitalized and those who
had not. We then applied these characteristics in a SEM to
account for the confounding effects of multicollinearity to
better understand factors of hospitalization. We found a
consistent, independent relationship between those with
improvement in negative emotions and reduced
hospitalization. We also found that patients with heart or
kidney disease were more likely to have reductions in
hospitalization when receiving peer support. Lastly, we
found an independent relationship between those with im-
provement in negative emotions and improvement in medi-
cation adherence.
Table 1 Clinical, biochemical, psychological and behavioural parameters stratified by hospitalization and baseline DASS-21 score
(Continued)
Hospital admission Baseline DASS-21 score
No (n = 484) Yes (n = 144) P value < 17 (n = 503) ≥17 (n = 124) P value
Intermediate 228 (49·9) 66 (48·5) 225 (47·3) 68 (58·6)
Low 29 (6·3) 5 (3·7) 26 (5·5) 8 (6·9)
Definitions of risk categories
1. Very High-Risk group with clinically evident cardiovascular-renal complications
2. High-Risk group with ≥3 stratification parameters and/or values above the high specificity cut off for any one of the risk scores
and/or eGFR< 60 ml/min/1.73 m2
3. Medium Risk group with two stratification parameters and values above the high sensitivity cut off but lower than the high specificity cut off for any of the risk
scores and eGFR between 60-90 ml/min/1.73 m2 and
4. Low-Risk group with one or fewer stratification parameter and values below the high sensitivity cut off for all risk scores and eGFR≥90 ml/min/1.73 m2
Definitions of complications and risk parameters:
Chronic kidney disease (CKD): estimated glomerular filtration rate 15–60 ml/min per 1.73 m2
Cardiovascular complication: coronary heart disease (myocardial infarction, unstable angina, percutaneous coronary intervention, coronary bypass operation),
stroke, peripheral vascular disease (lower extremity amputation, absent foot pulses with ankle:brachial ratio < 0.9 and/or lower limb revascularization)
Renal complications: End stage renal disease (ESRD) requiring dialysis and/or eGFR< 15 ml/min/1.73m2
Microalbuminuria: urinary albumin:creatinine ratio (ACR): ≥2.5 mg/mmol (men) and 3.5 mg/mmol (women)
Macroalbuminuria: urinary ACR > 25 mg/mmol
Retinopathy (typical retinal changes including vitrectomy, haemorrhages, and exudates)
Medication adherence: measured by 4-item Morisky Medication Adherence Scale where 4 is regarded as high adherence, score 2–3 as intermediate adherence,
and 0–1 as low adherence
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Fig. 2 (See legend on next page.)
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Peer support and its impact on comorbidity and
hospitalization
Our study suggests that those with more severe comor-
bidities may benefit more from peer support with
regards to reduced hospitalization. In patients with CKD
or CVD, peer support tended to improve psychometric,
self-care, and adherence measures, albeit short of signifi-
cance (data not shown). There is a paucity of research
that has examined the use of peer support to reduce dis-
ease burden and health care utilization in patients with
diabetes and CKD or CVD [25–27]. Our integrative ana-
lysis suggests that amongst all patients, patients with
CKD and/or CVD might benefit the most from peer
support to address their unmet needs.
Improving negative emotions on hospitalization and the
role of adherence
Negative emotions can lead to increased health care
utilisation in diabetes. In African Americans, the co-
occurrence of diabetes and depression tripled the number
of visits to emergency room and hospitalizations [28].
Other researchers have reported increased healthcare
costs [29] and premature mortality [30] in people with
diabetes and depression. Apart from depression, negative
emotions such as anxiety, are more common in people
with diabetes than healthy individuals [31]. Although
anxiety in adolescents with diabetes is associated with a
two-fold increase in hospital readmissions [32], similar
findings have not been well documented in adult popula-
tions. Likewise, the roles of peer support and negative
emotions in people with diabetes and their impact on
health care utilisation have not been well-studied.
Our data show that improved negative emotions inde-
pendently reduced hospitalizations and nonadherence, al-
though we could not demonstrate a direct path between
the latter two, likely due to small sample size. However, the
independent effect of negative emotion on treatment adher-
ence is noteworthy given the known impact of medication
adherence on diabetes outcomes. Medication adherence in-
dependently predicted mortality and healthcare utilisation
in a large British study of patients with type 2 diabetes re-
ceiving primary care [33]. In a survey of 2600 Chinese pa-
tients with type 2 diabetes, patients with depression and
poor glycemic control reported frequent hypoglycemia, a
common cause of hospitalization in diabetes, which was
mediated in part by poor treatment adherence [34]. In a
large study of insured Americans, improved medication ad-
herence reduced the odds of hospitalization or visits to an
emergency department by 13% after adjusting for co-
morbidities and socioeconomic status [35]. By converting a
non-adherent to an adherent population, the authors mod-
elled that close to a million hospitalizations and emergency
department visits could be prevented in the United States.
(See figure on previous page.)
Fig. 2 Kaplan Meier curves showing the cumulative proportions of people with type 2 diabetes requiring hospitalization. a Stratified by
assignment to peer support (PEARL). b Stratified by baseline negative emotions (DASS≥17). c Stratified by peer support and baseline negative
emotions. Pearl denotes peer support intervention. Depression Anxiety Stress Scale are denoted as DASS, using ≥17 points as the cut off for
those in the top quintile of subjects with negative emotions
Fig. 3 A structural equation model (SEM) showing the effects of change in negative emotions (DASS, PHQ9, CDDS) on hospitalizations (admission
episodes and stay) and medication adherence as well as the interaction between peer support and CKD/CVD on hospitalizations. Goodness of fit
indices of the model: pvalue of the Chi-squared test is 0.1330; the root mean square error of approximation is 0.019, the CFI value is 0.978. The
figure represents the estimates of latent variable relationships to outcome variables with pvalues in parentheses (refer to Table 2 for full details of
the SEM). Abbreviations: PHQ-9: 9-item Patient Health Questionnaire assessing depressive symptoms, DASS-21: 21-item Depression Anxiety Stress
Scale, CDDS-15: 15-item Chinese Diabetes Distress Scale, Medication Adherence: 4-item Morisky Medication Adherence Scale, CKD: Chronic Kidney
Disease as estimated glomerular filtration rate 15–60 ml/min/1.73 m , CVD: Cardiovascular disease including coronary heart disease (myocardial
infarction, unstable angina, percutaneous coronary intervention, coronary bypass operation), stroke, peripheral vascular disease (lower extremity
amputation, absent foot pulses with ankle:brachial ratio < 0.9 and/or lower limb revascularization)
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Although we did not show a significant interaction of
peer support and negative emotions in our own SEM
likely due to small sample size, the independent relation-
ships of improved negative emotions on hospitalization
reduction and improved medication adherence suggest
the need for more research on these inter-relationships.
Strengths and limitations
Strengths of this study include the collection of thorough
physical, psychological and behavioural assessments in
conjunction with documentation of healthcare utilisation,
which are important quality measures. We also provide a
detailed description of a technologically-enhanced inte-
grated care and peer support program within a real-world
setting. Regarding limitations, we found that some of the
hypothesized paths, for example, effects of peer support on
hospitalization through negative emotions and adherence,
were not supported by the final model, which might be
due to the strong confounding effect of JADE care through
comprehensive assessment and education in all patients.
Psychometric measurements were only measured between
pre and post intervention, so changes in negative emotions
could be modulated by hospitalization itself, thereby con-
founding the effect. We also recognized that the metabolic
parameters (BP, obesity, lipids) resulted in poor fit in the
SEM analysis, although univariate analysis showed that pa-
tients with or without hospitalizations had similar control
of cardiometabolic risk factors. Furthermore, the greater ef-
fect size of peer support on daytime than nighttime admis-
sions were not immediately evident. It is plausible that
peer support could only alleviate hospitalizations arising
from minor events which might be linked to negative
emotions, but not those due to serious illness. Despite
these limitations, the factor loadings, path coefficients, and
model statistics of our final SEM were significant, su-
pporting our conclusions on the relationships between
peer support, comorbidities, medication adherence, and
hospitalization. That said, due to the exploratory nature of
this post hoc analysis and the relatively small sample size,
the positive effects of a peer support intervention on
hospitalization require replication and more detailed
investigations.
In chronic diseases, factors other than negative emotions
and medication adherence, such as ethnic minority status
and incomes can also influence clinical outcomes. These pa-
rameters were not evaluated in our study. We also did not
measure and adjust for comorbidities unrelated to diabetes
or capture private health care utilisation. However, these un-
measured variables were expected to be equally distributed
Table 2 Summary of the estimated coefficients of the measurement and structural equation
Measurement equation
Latent variable Indicators Est. (P Value) Standard Error
Change in negative emotions CDDS 1.000 (ref) NA (ref)
PHQ-9 0.874 (< 0.001) 0.137
DASS-21 1.390 (< 0.001) 0.273
Hospitalisation Length of stay 1.000 (ref) NA (ref)
Frequency of hospitalisation 1.745 (< 0.001) 0.098
Structural equation
Dependent (outcome) variable Independent (explanatory) Variable Est. (P Value) Standard Error
Hospitalisation Change in negative emotions −0.218 (0.001) 0.065
Medication adherence 0.005 (0.833) 0.022
Age 0.013 (0.552) 0.022
Peer support −0.026 (0.576) 0.046
CKD 0.065 (0.580) 0.118
Heart disease −0.001 (0.993) 0.101
Peer support×CKD 0.833 (< 0.001) 0.171
Peer support× Heart disease 0.455 (0.001) 0.141
Medication adherence Change in negative emotions 0.240 (0.034) 0.113
Change in negative emotions Gender −0.022 (0.684) 0.054
Education 0.031 (0.316) 0.031
Peer Support 0.039 (0.471) 0.053
Goodness of fit indices of the model: p-value of the Chi-squared test is 0.1330; the root mean square error of approximation is 0.019, the CFI value is 0.978
CKD Chronic kidney disease defined by eGFR< 60 ml/min/1.73m2 or dialysis-dependence. Heart disease defined by a history of myocardial infarction, percutaneous
coronary intervention, and heart failure
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between the two groups given adequate randomization. The
generalizability of this study was limited by the volunteer
bias, as only 23% of eligible patients agreed to be peer sup-
ported, suggesting a more targeted approach is needed in
implementing these peer support programs.
Conclusion
In patients with type 2 diabetes receiving technologically-
enhanced multidisciplinary care, reduction in negative emo-
tions reduced hospitalization and medication nonadherence,
while peer support reduced hospitalization in patients with
cardiovascular-renal complications. Taken together, these
findings highlight the complex inter-relationships between
physical and psychological health and hospitalization, and
the importance of structuring care processes so as to iden-
tify high-risk patients who might benefit from additional
peer support.
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